BALAXI PHARMACEUTICALS LIMITED — Others, 05-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Balaxi Pharmaceuticals Limited reported no deviations in the utilization of funds raised through its preferential issue for the quarter ended September 30, 2024. The total amount raised was ₹47.57 crore, primarily for capital expenditure related to the construction of a pharmaceutical formulation plant in Hyderabad, alongside potential use for working capital and general corporate purposes. The company’s statements are accessible on its website.